Drug
Tomivosertib clinical trials
Also written eFT508.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
8 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 2
Effector Therapeutics (6) · Translational Research in Oncology (1) · Northwestern University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses tomivosertib is read from its arms, and is right about nine times in ten.
Testing it · 8
- Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)TerminatedPhase 1Northwestern UniversityNCT05744739Written as Tomivosertib
- An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate CancerTerminatedPhase 2Effector TherapeuticsNCT03690141Written as eFT508
- Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)Active, not recruitingPhase 2Effector TherapeuticsNCT04622007Written as Tomivosertib
- Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor TherapyCompletedPhase 2Effector TherapeuticsNCT03616834Written as Tomivosertib (eFT-508)
- Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast CancerCompletedPhase 1Translational Research in OncologyNCT04261218Written as tomivosertib
- A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological MalignanciesTerminatedPhase 1/2Effector TherapeuticsNCT02937675Written as Tomivosertib (eFT-508)
- A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid TumorsTerminatedPhase 1/2Effector TherapeuticsNCT02605083Written as eFT508
- A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCCTerminatedPhase 2Effector TherapeuticsNCT03318562Written as eFT508
Given in every arm · 1 — tomivosertib is usual care beside what is tested
Codes
What other systems call tomivosertib · ClinicalTrials.gg INT001079
- MeSH (NLM) C000630785tomivosertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) U2H19X4WBVTOMIVOSERTIBConfirmed FDA, NLM
- NCI Thesaurus C125062TomivosertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630785 | tomivosertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | U2H19X4WBV | TOMIVOSERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C125062 | Tomivosertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.